Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-TNF-α Biosimilars vs Originators in Juvenile Idiopathic Arthritis
2024-515557-22-00Phase 4Authorised
- Sponsor
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
- Start
- Aug 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of etanercept and adalimumab in juvenile idiopathic arthritis (JIA) (2 arms), sponsored by Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. Primary endpoint: Clinical remission at 18 months. Planned start Aug 2024; status: authorised.
02
Drugs
etanerceptadalimumab
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2024-515557-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515557-22-00.